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invasive cardiac testing to assess the likelihood of obstructive coronary artery dis-
ease (CAD). We hypothesized that use of a gene expression score (GES) would reduce 
diagnostic costs among non-acute symptomatic patients presenting to cardiolo-
gists. Methods: The IMPACT-CARD Trial (NCT01251302) prospectively enrolled 88 
patients without known CAD who presented with chest pain and related symptoms 
and were referred to one of six cardiologists. The cardiologist’s diagnostic strategy 
was evaluated before and after GES testing, and diagnostic testing in a matched 
historical cohort of 83 patients was extracted from medical records. The GES is a 
previously validated, blood-based diagnostic test that determines the likelihood 
of obstructive CAD, with a negative predictive value of 96% among low GES (≤ 15) 
patients. We estimated per-procedure costs from commercially insured patients in 
a large, national health claims database. We applied these costs to the tests per-
formed in the matched historical cohort and recommended in the prospective arm 
post-GES to calculate the cost of diagnostic evaluation in the trial. Given the rule-out 
nature of the GES, we focused this economic analysis on low GES patients. Results: 
There were 52 low GES study patients. The total cost of cardiac diagnostic testing 
in these patients was lower than in the 52 matched controls ($2,450 versus $1,735 
per patient, inclusive of the GES cost, p= 0.23), though the difference was not sta-
tistically significant. This finding represents 29% savings ($715 per patient) in car-
diac testing costs. No differences in clinical outcomes were observed between the 
groups. ConClusions: Physician use of the GES may be associated with reductions 
in diagnostic testing costs in low score patients. These savings reflect the potential 
economic utility of the GES in the diagnosis of obstructive CAD.
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objeCtives: Transcatheter Aortic Valve Implantation (TAVI) is a cost-effective life-
saving therapy for patients suffering from severe aortic stenosis (SAS) who are 
unable to undergo, or face prohibitively high risk to survival from, conventional 
open-heart surgery. The therapy is available in Canada on a limited basis, and access 
lags that in other developed nations. Access issues will become more acute in com-
ing years as the population further ages, though to-date no efforts have been made 
to quantify need for TAVI procedures and the potentially unavoidable deaths occur-
ring each year from capacity shortfalls. Methods: We developed a population-
based stock-and-flow simulation model using Microsoft EXCEL to quantify the 
prevalence and incidence of SAS, capacity to perform TAVI procedure, SAS patients 
longevity with and without TAVI and avoidable deaths from lack of access under 
various capacity-building scenarios for the provinces of Ontario, Quebec, British 
Columbia and Alberta. Our model was populated with data from published peer-
reviewed articles, the StatsCan CANSIM database and the support of the Cardiac 
Care Network. Results: We estimate that there is a severe shortage of capacity to 
perform TAVI procedures in relation to population needs that will result in 2,882 
avoidable deaths over the three years from 2014 to 2017. The gap between need 
and capacity is greatest in Ontario. ConClusions: An increase in the capacity to 
perform TAVI procedures is needed to reduce the number of access-related mortality 
in Ontario, Quebec, British Columbia and Alberta.
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objeCtives: Syncope is a common medical event that accounts for 1-3% of all visits 
to the emergency departments (ED), hospitalizations and falls, and is associated with 
high morbidity and deterioration of quality-of-life. Conventional testing strategies fail 
to diagnose underlying causes in more than 1/3 of cases, leading to repeat episodes 
and costly health care system interactions. We sought to better understand the bur-
den of unexplained syncope on four Provincial health care systems in Canada and 
evaluate the impact of adopting testing strategies centered on Insertable Cardiac 
Monitors (ICM) as an alternative to current practice. Methods: We evaluated the eco-
nomic burden and implications of alternative strategies for the provinces of Ontario, 
Quebec, British Columbia and Alberta using a multi-cohort Markov-based simulation 
model developed in Microsoft Excel. Our model was populated with data from peer-
reviewed papers, CIHI Patient Cost Estimator, the StatsCan CANSIM database and phy-
sician schedules of fees. Results: We estimate that between 2014 and 2023, syncope 
will affect 223,000 people each year across the four provinces, and account for 97,000 
ED visits, 11,000 hospitalizations and 6,000 falls annually in this period. A total of 1.5 
million diagnostic tests will be performed under conventional strategies, compared 
to 626 thousand tests if every syncope patient post-2014 were assigned ICM following 
an initial unsuccessful diagnosis (43% reduction). The ICM strategy would also elimi-
nate 12% of blackouts, 9% of falls, and 21% of ED visits and hospitalizations related 
to Syncopal events. The proportion of patients diagnosed would increase from 15% 
to 47% at 36 months, and the strategy would be largely cost-neutral with an average 
annual reduction of $43M per year in Syncope-related expenditures. ConClusions: 
We find that the burden of unexplained Syncope on Canadian health care systems is 
substantial, and wider utilization of ICMs in diagnosis could reduce this burden while 
improving the patient experience.
PCV121
real WOrld data: a tOOl fOr deCIsIOn maKIng In health Care
Mussolino F., Vaz P.V. , Pepe C., Junqueira M.
NewBD/Medinsight – Grupo Resulta, São Paulo, Brazil
objeCtives: This study aims to stimulate the use of secondary data in health eco-
nomic analyses, based on a better understanding of available possibilities using 
Brazilian public health databases (DATASUS) and to develop a case study focused on 
the treatment of patients with acute myocardial infarction (AMI). Methods: This 
study was conceived as a transversal observation of the available public databases, 
including outpatient and inpatient information. Conducting studies using real 
world data is possible due to the identification of the individual under treatment. 
This identification does not allow determining the patient’s identity, but allows 
tracking patients’ treatment and outcomes. The total amounts of spending in the 
outpatient and inpatient settings have been analyzed. Besides, a case study was 
developed focusing on patients hospitalized due to AMI. The quantity of treatments 
performed, treatment centers involved and the associated mortality were evaluated. 
High volume centers (HVCs) were compared to low volume centers (LVCs). Results: 
In the outpatient setting, about 3 million patients were treated in 2011 resulting in 
expenses of approximately 8.7 billion dollars. In the inpatient setting, more than 9 
million patients’ records were found, resulting in expenditures of around 13.1 billion 
dollars. In 2012, 57,133 hospitalizations due to AMI were identified in 2,138 centers. 
Eighty per cent of the hospitalizations occurred in 25% of the centers. In the HVCs 
an average of 87 hospitalizations due to AMI were recorded per year versus 7 in the 
LVCs. The mortality rate due to AMI was lower in the HVCs when compared to the 
LVCs (14.9% vs 15.8%; p< 0.05) and the average length of stay was higher (8.7 vs 5.2 
days). ConClusions: Health managers should use the thorough analyzes based 
on secondary data provided by DATASUS for decision making and to better allocate 
scarce resources in health care.
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objeCtives: Medication reconciliation is a necessary process for the delivery of 
optimal patient care, yet can be difficult to do in the primary care setting due to 
limited time and resources. Dramatic improvements in health information technol-
ogy may facilitate accurate and real-time medication reconciliation. The purpose of 
this study is to determine the potential impact of linked pharmacy claims within to 
the primary care electronic health record (EHR) to inform medication reconciliation 
in primary care practice. Methods: We conducted a retrospective cohort study in 
patients that were prescribed a new antihypertensive between January 2011 and 
September 2012. We compared patients’ active medications as recorded in a primary 
care practice EHR with those that were listed in pharmacy claims data available 
through the EHR. Only medications that were active in the 120 days prior to the new 
antihypertensive were considered. Medications that appeared in one data source 
but not the other were categorized as discrepancies. The primary outcome was the 
presence of at least one discrepancy. Predictors of discrepancy risk were calculated 
through logistic regression. Results: A total of 609 patients qualified for study. 
Amongst all patients, 2947 medications were reconciled, with 1401 as discrepancies. 
The majority of patients (468, 76.9%) had at least one discrepancy. Predictors of the 
risk of having discrepancies included total medication count (OR: 0.17, p= < 0.0001), 
at least one non-cardiovascular related comorbidity (OR: 0.84 p= 0.0001) and a hos-
pitalization in the previous year (OR: 0.48, p= 0.007). ConClusions: A high rate of 
medication discrepancies was found amongst patients, along with significant pre-
dictors of occurrence. The use of linked pharmacy claims was able to show a more 
complete picture of a patient’s medication use patterns. Such automated solutions 
could be used to screen available data sources to uncover discrepancies and identify 
patients who may benefit from tailored clinical interventions.
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objeCtives: Pharmaceutical companies adopt distinctive marketing strategies to 
advertise drugs for hypertension and psychosis. This study explored the variance 
in stereotypes related to gender disparity and activity status (passive and active) 
used in video direct-to-consumer advertisements for anti-psychotics and statins 
class of drugs. Methods: Fifty-eight unique video DTCA aired on NBC and CNN 
evening news were analyzed. The Vanderbilt TV News Archive Database was utilized 
to obtain random samples from each year which constituted to final sample of nine 
anti-psychotic and forty-nine statins ads aired between 1st January 1998 and 31st 
December 2011. Inter-rater reliability was assessed using Cohen’s Kappa and was 
found to be acceptable for the variables used in the instrument. Data was analyzed 
using Fischer Exact test using SAS 9.3®. Results: Out of the 58 ads, 41-ads por-
trayed males and 32-ads portrayed females as the primary character. The propor-
tion of male character was significantly higher in statins ads compared to ads for 
antipsychotics (79.59 % vs. 22.22 %, p= 0.0016). However, the proportion of female 
character was significantly greater in ads for antipsychotics compared to statins 
(88.89 % vs. 48.98%, p= 0.034). In addition, a female character with passive status was 
significantly higher in antipsychotic ads compared to statins (66.67 % vs. 32.65 %, 
p= 0.055). In contrast, a male character with active status was significantly greater 
in statins compared to antipsychotics (38.78 % vs. 0 %, p= 0.0012). ConClusions: 
Gender and activity status stereotypes are quite prevalent in both anti-depressants 
and cardiovascular drugs. Males with active status were more likely to be featured 
in statins whereas female characters with passive status were more likely to be 
featured in anti-psychotics. Stereotypes in DTCA may potentially bias the decision 
making ability and prescribing behavior of physicians.
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objeCtives: In order to investigate real-world values data; blood pressure, LDL-c, 
and HbA1c, in Japan from various perspectives and to assess the degree to which 
health condition in Japan is reflected in database, we conducted a comparative 
assessment using three databases: Minacare database, a large database containing 
health care checkup results from employment-based health insurance recently 
developed, and the publicly available two nation-wide databases. Methods: A 
retrospective, cross sectional study using the Japanese health care checkup data-
base developed by MinaCare Co. Ltd. was designed to investigate the distribution 
of the real-world values of BP, LDL-c, and HbA1c in Japan. The data were compared 
to those in Specific Health Checkups and Specific Health Guidance (MHLW-SH) and 
National Health and Nutrition Survey (MHLW-H&N). Results: There were 232,515 
subjects with health care checkup results in 2011 MinaCare database. The propor-
tion of subjects with SBP≥ 140 mmHg, LDL-c≥ 140 mg/dL, and HbA1c≥ 6.1% generally 
increase with age; in the 55-60 year age range, the proportions were 19.0% (males) 
and 12.2% (females) for SBP, 27.2% and 42.7% for LDL-c, and 13.5% and 5.4% for 
HbA1c, respectively. The MinaCare database was mostly comparable to MHLW-SH 
and MHLW-H&N databases. However, some notable differences were seen for MHLW-
H&N compared to MinaCare and MHLW-SH in the values of BP and lipid param-
eters. ConClusions: Analysis of MinaCare database indicated that substantial 
proportions of subjects have BP, LDL and HbA1c levels that are not well controlled 
in accordance with the Japanese guidelines. The results were generally consistent to 
the national databases. In light of the characteristics of MinaCare database such as 
the low selection bias, large sample size, wide age distribution, and high flexibility 
in the analysis of subject-level data, the database is highly valuable in studying the 
health status of the population insured by the employment-based health insurance.
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COmParIsOn Of atrIal fIbrIllatIOn deCIsIOn sUPPOrt tOOls and 
gUIdelInes Used tO gUIde antICOagUlatIOn theraPy fOr PatIents 
WIth nOnValVUlar atrIal fIbrIllatIOn
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objeCtives: The American College of Chest Physicians, the European Society 
of Cardiology guidelines, and published decision support tools by LaHaye and 
Casciano offer recommendations to guide oral anticoagulant (OAC) treatment in 
patients with atrial fibrillation (AF). The aim of our study is to compare the predic-
tive validity of these aids by contrasting the net clinical benefit when OAC use is 
concordant/discordant with each of the aids. Methods: A cohort study using the 
2006-2013 Lifelink claims data was used to compare the net clinical benefit (NCB) 
of AF patients. NCB is the difference in event rates of composite events (thrombo-
embolic stroke and major bleed events per 10,000 person years) between patients 
who are concordant and those who are discordant with the guideline/tool recom-
mendations. Cox proportional hazard models were used to assess the relative risk 
of composite thromboembolic and bleed events adjusted for potential confound-
ers. Results: A total of 11,315 AF patients contributing 27,801 person years met 
the study inclusion criteria. The NCB of patients concordant with recommendations 
of the LaHaye tool (34.81[C.I= 33.4-36.23]) was highest followed by American guide-
lines (22.75[C.I= 21.40-24.17]), Casciano tool (16.99[C.I= 15.57-18.40]) and European 
guidelines (3.94[C.I= 2.52-5.35]). By restricting the definition of composite events to 
ischemic stroke and intracranial hemorrhage; the NCB of patients concordant with 
American guidelines (24.20[C.I= 22.88-25.52]) was highest followed by Casciano tool 
(17.07[C.I= 15.75-18.38]), LaHaye tool (14.30[C.I= 12.99-15.62]) and European guide-
lines (11.25[C.I= 9.93-12.57]). There was no significant decrease in the risk of com-
posite events associated with concordant OAC use/non-use for any of the decision 
aids after multivariate adjustment. ConClusions: These results suggest that OAC 
use/non-use consistent with any of the tools led to net clinical benefits but the rank 
order depended on the composite outcomes selected. However, the benefit vanished 
after multivariate adjustment. Larger studies are warranted before any one OAC 
decision aid can be recommended to routinely guide OAC treatment decisions.
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fOr Oral antICOagUlant Use amOng PatIents WIth atrIal 
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objeCtives: Published atrial fibrillation (AF) guidelines and decision tools offer 
oral anticoagulant (OAC) recommendations however they consider stroke and 
bleed risk differently. The aims of our study are to (i)empirically compare the treat-
ment recommendations by the American College of Chest Physicians guidelines, 
the European Society of Cardiology guidelines, and two published decision tools 
published by Casciano and LaHaye and (ii) to compare the concordance of OAC 
use with their recommendations. Methods: A cross sectional study using the 
2006-2013 Lifelink claims data was used to contrast the treatment recommenda-
tions of these AF-OAC decision aids. CHADS2VASc and HAS-BLED algorithms were 
used to stratify 11,315 AF subjects into 9 stroke and bleed risk groups to study the 
variation in treatment recommendations. The concordance of actual OAC use with 
each of the decision aid’s treatment recommendations was compared. Results: 
The European guidelines recommended OAC most often (84.96%) and a conserva-
tive LaHaye tool recommended warfarin OAC the least often (13.41%). None of the 
decision aids recommended OAC for subjects with low stroke risk (CHADS2VASc= 0). 
However, OAC treatment recommendations varied considerably when stroke risk 
was moderate or high (CHADS2VASc> 0). For example, the LaHaye tool never recom-
mended warfarin OAC for persons with CHADS2VASc= 1 irrespective of bleed risk, 
however, the European guidelines preferred OAC for persons with CHADS2VASc= 1 
and a HAS-BLED< 3. Actual OAC use was most consistent with the Casciano tool 
(49.43%) and was least consistent with the LaHaye tool (44.52%). ConClusions: 
OAC prescribing could be improved as actual OAC use/non-use was often discordant 
with all the recommendations. There is considerable variability in OAC treatment 
recommendations by the AF guidelines and decision tools when ischemic stroke risk 
is moderate or high. Empirical evidence is needed to compare the outcomes of OAC 
treatment recommendations by each of these decision aids before implementing 
one of these to inform clinical decisions.
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Use Of PrOdUCt lIfe CyCle (PlC) tO Understand adVertIsIng 
strategIes Used by PharmaCeUtICal COmPanIes: a PIlOt stUdy
Kumari P., Muzumdar J.M., Nania A., Nayak R., Shanbhag P.
St. Johns University, Fresh Meadows, NY, USA
objeCtives: Pharmaceutical companies utilize various promotional strategies to 
advertise a drug during its patent life. Study purpose was to understand these strate-
gies by exploring the content of drug advertising using the framework of Product 
Life Cycle (PLC). During different stages of PLC, this study assessed drug ads for 
the following: (1) type of characters appearing in the ad, (2) source of information 
(SOI) for the drug, and (3) ad appeals (rational vs. emotional). Methods: Unique 
ads of Pfizer, Inc. drug Lipitor (Atorvastatin), aired during CNN evening news (from 
Jan 1st ’96 – Nov 30th ’11 [patent life of Lipitor]), were evaluated. The Vanderbilt TV 
News Archive provided the advertising content. PLC phases were defined as fol-
lows: introduction and growth (Phase-I: 1999-2002); maturity (Phase-II: 2003-2006); 
and decline (Phase-III: 2007-2011). Code sheet was developed using prior literature 
and pilot-tested for the final study. Four coders were trained in coding procedures. 
Reliability was measured with Cohen’s kappa. Data were analyzed using descrip-
tive statistics and cross-tabulations. Results: Twenty-one (phase-I: 2; phase-II: 7; 
phase-III: 12) unique product-specific ads were analyzed. Researchers of the adver-
tised drug appeared more in phase-II [3 (43%) of 7 vs. 3 (25%) of 12 in phase-III)]. 
Person with medical condition appeared more in phase-III [9 (75%) of 12 vs 4 (57%) of 
7 in phase-II)]. In all three phases an anonymous voice provided drug information. 
Researchers were a SOI in phase-II [3 (43%) of 7 ads] and a person with medical con-
dition was a SOI in phase-III [7 (58%) of 12]. The appeal of phase-II ads was rational 
compared to ads in phase-III [4 (57%) of 7 vs. 5 (43%) of 12 ads]. ConClusions: 
Distinctive ad strategies were observed throughout the PLC of Lipitor. These dif-
ferentiated strategies coincided with shifts in PLC phases, which indicate a change 
in ads based on the phase of PLC.
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eValUatIOn Of medICal QUalIty based On readmIssIOns WIthIn 30 
days amOng benefICIarIes In Central IllInOIs
Asche C.1, Ren J.1, Hippler S.E.2
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objeCtives: To evaluate the medical quality of a Central Illinois health care 
system by developing a predictive model to identify those patients who might 
be more likely to be readmitted with 30 days of discharge based upon their fac-
tors, determinants and demographic/clinical characteristics. Methods: This is 
a retrospective study integrating the information compiled in a Central Illinois 
hospital administrative database from 2010 to 2013 of patients admitted with 
acute myocardial infarction (AMI), Heart Failure (HF) or Pneumonia, capturing 
data including readmissions within 30 days, diagnosis, treatment, gender, age, 
education, race, medical insurance, health care provider, specific comorbidities 
etc… A multivariable generalized linear model and Bayesian analysis were used to 
predict adjusted hospital readmission rates including all-cause, AMI, HF and pneu-
monia. Results: The average adult readmission rates were 15.2% (1554/10244) 
for all-cause, 8.9% (272/3058) for AMI, 15.6% (583/3740) for pneumonia and 20.3% 
(699/3446) for HF. Among adults higher readmission rates were significantly more 
likely to occur among Black Americans (21.2% of all readmissions), those who have 
separated, divorced or widowed (17% of all readmissions), elderly with AMI, those 
individuals living in metropolitan areas (16.6% of all readmissions), underweight 
individuals (26% of all readmissions), and those individuals with longer length 
of stay and comorbidities. The HF and AMI specific admission data were utilized 
to develop and test the predictive model. The sensitivity and specificity were 
56.1% and 57.6% for HF and 67.9% and 66.6% for AMI, respectively. ConClusions: 
Predictive modeling can serve to identify patients who could be more likely to be 
readmitted. More information is required to improve the accuracy of the model. 
The model could be operationalized in a hospital setting to identify high-risk 
individuals who may benefit from interventions upon discharge.
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hOsPItal QUalIty sCOres VersUs medICare Charges and 
reImbUrsement – What Is the assOCIatIOn?
Miyasato G.S, Wang Z., Meckley L.M.
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objeCtives: In 2011, the US Centers for Medicare and Medicaid Services (CMS) 
established the Hospital Value-Based Purchasing (HVBP) program in which hospitals 
were assigned quality scores related to their treatment of inpatients. The primary 
objective of this study was to measure, among acute myocardial infarction (AMI) 
and heart failure (HF) inpatients, the association between hospital quality of care 
scores and the difference between hospital charges and reimbursement amounts 
(the Delta). This research has potential implications related to inpatient procedure 
quality measures and hospital charging behavior. Methods: The Delta between 
hospital charges and reimbursement was calculated for patients with an AMI or HF 
from 2011 Medicare inpatient claims. Quality was assessed with CMS’s 2011 Hospital 
Compare AMI and HF quality component scores. To measure the adjusted associa-
tion between the Delta and quality scores, generalized linear mixed models were fit 
separately for AMI patients and HF patients. The models controlled for both patient 
and hospital characteristics. Results: The AMI model was fit using 110,076 claims 
across 1,383 hospitals. After controlling for patient and hospital factors, each 1-point 
increase in AMI quality score yielded a 0.5% increase in Delta (p-value = 0.01). The 
HF model was fit using 468,974 claims across 2,813 hospitals. The adjusted HF model 
revealed that a point increase in HF quality score yielded a 1.0% increase in Delta 
